Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446546 | 1.00 | HTR3A (0.81) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16446343 | 1.00 | HTR3A (0.81) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL2884603 | 0.98 | HTR3A (0.79) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22778230 | 0.94 | HTR3A (0.73) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL16446401 | 0.92 | HTR3A (0.76) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL26690667 | 0.90 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL6902944 | 0.90 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3 | |
| SCHEMBL12536782 | 0.90 | HTR3A (0.66) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL447190 | 0.90 | HTR3A (1.00) | HTR3ASLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL29908691 | 0.88 | HTR3A (0.96) | HTR3ASLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778193-B | Synthesis method of (S) -3- (4-chlorophenyl) -piperidine | 康化（上海）新药研发有限公司 | 2024-03-12 | — | — | CN | claimed |
| CN-112778193-A | Synthesis method of (S) -3- (4-chlorphenyl) -piperidine | 康化（上海）新药研发有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-105452233-A | Piperidine and azepane derivatives as prokineticin receptor modulators | TAKEDA PHARMACEUTICALS CO | 2016-03-30 | — | — | CN | claimed |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| CN-112778193-B | Synthesis method of (S) -3- (4-chlorophenyl) -piperidine | 康化（上海）新药研发有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112778193-B | Synthesis method of (S) -3- (4-chlorophenyl) -piperidine | 康化（上海）新药研发有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-112778193-B | Synthesis method of (S) -3- (4-chlorophenyl) -piperidine | 康化（上海）新药研发有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| CN-112778193-A | Synthesis method of (S) -3- (4-chlorphenyl) -piperidine | 康化（上海）新药研发有限公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-1984344-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION | 2008-09-18 | — | — | US | disclosed |
| WO-2008027466-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | SCHERING CORPORATION (US) | 2008-03-06 | — | — | WO | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
| WO-2007089335-A2 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICAL INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| CN-1922183-A | Nitrogenous fused heteroaromatic ring derivative | BANYU PHARMA CO LTD (JP) | 2007-02-28 | — | — | CN | disclosed |
| US-4077958-A | ANTIDEPRESSANTS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4007191-A | ANTIDEPRESSANT | E. R. SQUIBB & SONS, INC. (US) | 1977-02-08 | — | — | US | disclosed |
| US-3935227-A | ANTIDEPRESSANTS, ANTIANXIETY, ANTIINFLAMMATORY AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080226618-A1 | HYDANTOIN DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | LPXN, HAX1, LCT | HTR3A 3061/4885CYP2D6 710/4885SLC6A2 1395/4885 |
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | HTR3A 3838/4885CYP2D6 3618/4885SLC6A2 4119/4885 |
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | HTR3A 1580/4885CYP2D6 2841/4885SLC6A2 4827/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | HTR3A 15/4885CYP2D6 165/4885SLC6A2 26/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | HTR3A 4669/4885CYP2D6 247/4885SLC6A2 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.